March 4, 1997 |
IDEC Pharmaceuticals Corp. and Genentech Inc. filed for Food and Drug Administration approval to market a new lymphoma treatment that would be the first monoclonal-antibody product in the U.S. to fight cancer. The treatment, rituximab, is for patients who have relapses of slow-growing non-Hodgkin's lymphoma, a fatal cancer of certain kinds of cells in the body's immune system.
March 20, 2001 |
Corixa Corp. said it would cut its work force and take a charge against earnings after the Food and Drug Administration requested more data on an experimental drug that uses a cloned antibody to deliver radiation directly to cancer tumors. The request for additional safety and other data on Bexxar, considered the most important drug in the company's pipeline, adds at least a year to the timeline for approval, analysts said.
May 7, 1996
Companies with highest ratio of stock market value to sales. *--* 4/19/96 1995 Price/ Mkt. value Revenue sales Rank Company ($ millions) ($ millions) ratio 1 Pixar Animation Studios 785 12 66 2 Netscape Communications 4,305 78 52 3 ThermoLase Corp. 1,205 25 46 4 Xylan Corp. 2,539 30 46 5 Forte Software Inc. 867 23 38 6 Ascend Communications 6,367 150 37 7 Objective Sys. Integrator 1,273 36 37 8 San Francisco Co. 303 11 27 9 Atari Corp. 362 15 25 10 VISX Inc. 470 17 23 11 Protein Design Labs Inc.
September 20, 2002 |
British drug maker GlaxoSmithKline said Thursday that it settled litigation against Genentech Inc. that claimed its rival infringed patents covering monoclonal antibodies--cells grown in large fermentation tanks that can be programmed to attack disease. The companies did not disclose details of the confidential settlement, which ends two separate legal actions. As a result of the settlement, Glaxo dropped its appeal of a May 2001 jury verdict in favor of Genentech.
July 24, 2001 |
Idec Pharmaceuticals Corp. said Monday that a government advisory panel will review its radioactive treatment for non-Hodgkin's lymphoma on Sept. 11. The review is important for Idec, as the Food and Drug Administration typically follows the recommendation of its committees. If approved by the FDA, the drug, known as Zevalin, would be the first of its kind. It also would be the first drug that Idec would manufacture and market on its own.
March 14, 2001 |
Shares of biotechnology companies, including Amgen Inc. (ticker symbol: AMGN) and IDEC Pharmaceuticals Corp. (IDPH), rebounded Tuesday after analysts issued positive ratings on the stocks, which have been beaten down amid the recent sell-off on Nasdaq. Amgen's shares rose $3.75 to $65.06, while IDEC was up $2.31 at $48, both on Nasdaq. The Nasdaq biotech index was up almost 5% for the day.